国际肿瘤学杂志

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (2): 88-90.doi: 10.3760/cma.j.issn.1673-422X.2015.02.003

• 论著 • 上一篇    下一篇

CIK细胞联合白细胞介素-2对非小细胞肺癌患者免疫功能及生命质量的影响

薛鸣,郭明坤   

  1. 453000 河南省新乡市中心医院放疗科
  • 出版日期:2015-02-08 发布日期:2015-02-02
  • 通讯作者: 薛鸣 E-mail:xuemingcn@163.com

Effect of adoptive immunotherapy with CIK cells combined with interleukin-2 on immunologic function and life qualities of patients with nonsmall cell lung cancer

Xue Ming, Guo Mingkun   

  1. Department of Radiation Oncology, Xinxiang Central Hospital of Henan Province, Xinxiang 453000, China
  • Online:2015-02-08 Published:2015-02-02
  • Contact: Xue Ming E-mail:xuemingcn@163.com

PDF

1474

被引次数

7

摘要： 目的观察细胞因子诱导杀伤(CIK)细胞联合白细胞介素2（IL2）对非小细胞肺癌（NSCLC）患者免疫功能及生命质量的影响。方法将符合条件的38例患者按相似条件配对分为两组。治疗组患者放化疗后接受CIK细胞联合IL2治疗，对照组仅行放化疗。观察CIK细胞回输后患者的不良反应及生命质量改善情况。取两组患者放化疗结束时(CIK细胞治疗前)及放化疗结束后3个月 (CIK细胞治疗已结束)两个时间点，分别观察治疗组和对照组患者免疫指标(外周血CD3+、CD4+、CD8+T细胞百分比，CD4+/CD8+及Th1/Th2比值)。结果治疗过程中未出现明显不良反应，治疗组19例患者经CIK细胞联合IL2治疗后精神改善者18例，食欲改善者15例，睡眠改善者12例，疲乏症状改善者3例。治疗组患者CD3+、CD4+T细胞百分比升高［（66.39±9.22）%∶（42.98±7.23）%， t=5.45，P=0.00；（32.27±3.75）%∶（26.38±2.51）%， t=5.73，P=0.00］，CD8+T细胞百分比降低［（17.51±1.85）%∶（20.90±2.31）%， t=5.21，P=0.00］，CD4+/CD8+比值上调、Th1/Th2正置［（1.86±0.32）∶（1.27±0.19）， t=7.13，P=0.00；（1.15±0.48）∶（0.91±0.30）， t=2.42，P=0.02］，与对照组比较差异均有统计学意义。结论CIK细胞联合IL2治疗可改善NSCLC患者免疫功能，并在一定程度上改善患者的生命质量，且无明显不良反应。

关键词: 癌, 非小细胞肺, 免疫疗法, 细胞因子诱导杀伤细胞

Abstract: Objective To investigate the changes of immunologic functions and life qualities after the autocytokine induced killer (CIK) cells combined with interleukin2(IL2) being transfused back to the patients with nonsmall cell lung cancer (NSCLC). MethodsThirtyeight NSCLC patients were enrolled, and 19 patients received not only chemotherapy and radiotherapy but also adoptive immunotherapy with CIK cells combined with IL2 compared with the other 19 patients who only accepted radiotherapy and chemotherapy. The changes of immunologic functions and life qualities after the CIK cells combined with IL2 being transfused back to the patients with NSCLC were observed. Immune targets of the treatment group and control group, such as peripheral blood CD3+, CD4+, CD8+ T cell percentage, ratio of CD4+/CD8+ and Th1/Th2, were observed at the end and after 3 month of the radiation and chemotherapy. ResultsBoth of the two groups were neither having obvious adverse reactions. After CIK cells combined with IL2 treatment, the life qualities of patients improved, such as 18 cases of  mental improvement, 15 cases of appetite improvement, 12 cases of sleep improvement, and 3 cases of fatigue symptoms improvement. The percentage of CD3+, CD4+ cells in the treatment group increased ［（66.39±9.22）% vs （42.98±7.23）%， t=5.45，P=0.00；（32.27±3.75）% vs （26.38±2.51）%， t=5.73，P=0.00］, the percentage of CD8+ cells declined ［（17.51±1.85）% vs （20.90±2.31）%， t=5.21，P=0.00］, the rate of CD4+/CD8+ increased and the rate of Th1/Th2 obversed ［（1.86±0.32） vs （1.27±0.19）， t=7.13，P=0.00；（1.15±0.48） vs （0.91±0.30）， t=2.42，P=0.02］. There were significant differences between the two groups. ConclusionAdoptive immunotherapy with CIK cells combined with IL2 is safe in clinical, which can improve the immunologic functions and life qualities of the patients with NSCLC.

Key words: Carcinoma, nonsmallcell lung, Immunotherapy, Cytokine induced killer cells